Calendario›CYTK›CK-3773274

CK-3773274

A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects

Ensayo de CYTOKINETICS INC en Symptomatic Obstructive Hypertrophic Cardiomyopathy · Healthy Subjects (del registro, en inglés).

Fase

Fase 1

Estado

Completado

Participantes

114

previstos

Centros

1

Fin del objetivo primario

ene 2020

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, triple ciego. Comenzó en dic 2018.

Qué mide

Incidence of Adverse events and Safety Signals observed during single and multiple ascending doses of CK-3773274 administered orally to healthy adult subjects. (SAD Cohorts: Day -1 - Day 10; CYP2D6 Cohort: Day -1 - Day - 24; MAD Cohorts: Day -1 - Day 27; Food Effect Cohort: Day -1 - Day 24; relative Bioavailability Cohort: Day -1 - Day 29) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThe purposes of this study are to: 1. Learn about the safety of CK-3773274 after a single dose and multiple doses in healthy subjects. 2. Learn how healthy subjects tolerate CK-3773274 after a single dose and multiple doses. 3. Find out how much CK-3773274 is in the blood after a single dose and multiple doses. 4. Determine the effect of doses of CK-3773274 on the pumping function of the heart. 5. Evaluate the effect of cytochrome genetic variants on how the body metabolizes CK-3773274. 6. Evaluate the effect of a meal on how much CK-3773274 is in the blood in healthy adult subjects. 7. Evaluate whether the amount of CK-3773274 in the blood is the similar for both the tablet and granules in capsule forms of the drug.

Más ensayos de CYTK

Todos los de CYTK, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT03767855), actualizada en ene 2025.